Immunotherapy treatment was effective at reducing attack recurrence in patients with NMOSD but was less effective for MOGAD, a study found.

Researchers found that pediatric male patients with hemophilia are at a greater risk of falls due to poor dynamic balance.

Evaluating the impact of environmental factors on CLL risk presents unique challenges, including the extended latency period between exposure and disease manifestation, as well as the uncertainty ...

Artificial intelligence may improve the diagnostic rates of AAV in a cost-effective manner. Deep learning models may be useful in identifying potential cases of antineutrophil cytoplasmic antibody ...

The dried blood spot test approach requires no special handling or storage and can be carried out with capillary instead of venous blood. A new study has found that a novel functional C1-INH (fC1-INH) ...

All patients presented to the hospital with acute myelitis in the form of weakness in the arms and legs but no concurrent visual complaints. A team of researchers from Ethiopia presented a case series ...

The researchers used latent class analysis with 10 indicator variables such as ANCA subtype and tracheal and bronchial involvement to identify subtypes of AAV. A new study has employed latent class ...

All 5 patients who switched from eculizumab remained relapse-free while being treated with satralizumab. Satralizumab after eculizumab is effective and well tolerated in patients with neuromyelitis ...

In patients with In Becker muscular dystrophy BMD) and myotonic dystrophy type 1, the amplitude ratio of the movement-related potential did not change significantly when the duration of the ...

Pola-BR was particularly effective in those with severe disease and had a better ORR in older patients. Polatuzumab vedotin in combination with bendamustine and rituximab (Pola-BR) is an effective ...

Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Kristin Hatcher, director of pediatric and rare diseases at the Global Liver Institute.Hatcher has both alpha-1 antitrypsin ...

Adjusted analysis found no statistically significant difference in grade 3+ hematologic adverse events between the older and younger cohorts. Standard frontline rituximab, cyclophosphamide, ...